Related Experiment Video

Updated: Feb 26, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K

Association Between Patatin-Like Phospholipase Do-Main-Containing Protein-3 Variant and Cardiovascular Disease Risk

Chia-Hui Yu1, Gwo-Tarng Sheu2, Chien-Feng Li3

  • 1School of Nursing, College of Medicine Chung Shan Medical University Hospital Taichung Taiwan.

Health Science Reports
|February 25, 2026
PubMed

Insights

Single-nucleotide polymorphisms in the PNPLA3 and APOE genes are linked to higher cardiovascular disease (CVD) risk in people with HIV (PLWH) on antiretroviral therapy (ART). Genetic screening may personalize treatment and improve long-term CVD outcomes for PLWH.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Infectious Diseases

Background:

  • People living with HIV (PLWH) on antiretroviral therapy (ART) have an elevated risk of cardiovascular disease (CVD).
  • Genetic factors may influence CVD risk in this population.
  • Understanding these genetic associations is crucial for risk stratification and management.

Purpose of the Study:

  • To investigate the association between specific single-nucleotide polymorphisms (SNPs) in lipoprotein-related genes and CVD risk.
  • To evaluate the impact of these genetic variations on CVD risk scores in PLWH undergoing ART.

Main Methods:

  • Genotyping of four SNPs (ABCB1 rs1045642, APOE rs429358 and rs7412, PNPLA3 rs738409) in 337 PLWH.
  • Calculation of CVD risk using the D:A:D model.
  • Statistical analysis (ANCOVA) to assess associations between SNPs and CVD risk scores, adjusting for covariates.

Main Results:

  • PNPLA3 (rs738409) was significantly associated with higher 10-year CVD risk scores (p=0.03).
  • APOE (rs7412) T allele showed borderline associations with increased CVD risk (p=0.07-0.09).
  • No significant associations were found for ABCB1 or APOE (rs429358).

Conclusions:

  • SNPs in PNPLA3 and APOE may contribute to increased CVD risk in PLWH on ART.
  • Genetic screening could enable personalized treatment strategies for improved long-term CVD outcomes.
  • Further research is warranted to elucidate the mechanisms linking these SNPs to CVD risk.
Abstract

Keywords:
HIVantiretroviral therapyapolipoprotein Ecardiovascular diseasepatatin‐like phospholipase do‐main‐containing protein‐3 variantpharmacogeneticspolymorphisms

More Related Videos

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V311:10

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3

Published on: December 27, 2010

12.8K
Peptide-based Identification of Functional Motifs and their Binding Partners14:28

Peptide-based Identification of Functional Motifs and their Binding Partners

Published on: June 30, 2013

13.1K

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
416
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
57
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
755
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
474
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.3K